Work

Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.7053

Authors: Martin C. Müller, Michele Baccarani, Michael W.N. Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M Rivera, Timothy Piers Clackson, Frank G. Haluska, Jorge E. Cortes

Institutions: Medizinische Fakultät Mannheim, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Utah, Huntsman Cancer Institute, Inserm, Centre Hospitalier Universitaire de Poitiers, Jena University Hospital, South Australian Health and Medical Research Institute, The University of Adelaide, University of California, San Francisco, University of Michigan, ARIAD Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2721117261

Cites:

Cited by:

Related to: 10